Prazepam in the treatment of anxiety: a placebo-controlled multicenter evaluation.
A double-blind randomized multicenter parallel group comparison of prazepam in divided doses vs. placebo was conducted by 15 investigators among 847 patients presenting with anxiety alone or concurrent with other medical illnesses. Study groups were well matched for age, sex and level of pre-treatment symptomatology. Efficacy evaluation by a physician questionnaire included serial assessment of global improvement plus 10 target signs/symptoms during the 2 to 4 weeks of treatment. Prazepam was statistically significantly superior to placebo as shown on final on-treatment scores for global improvement ratio and for the target symptoms of anxiety, tension, irritability/hostility, depressive mood, insomnia and somatization.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001007:Anxiety / Q000188:drug therapy*; D003863:Depression / Q000188:drug therapy; D004194:Disease / Q000523:psychology; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006791:Hostility / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011222:Prazepam / Q000009:adverse effects / Q000627:therapeutic use*; D012107:Research Design; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy; D013997:Time Factors
D011222:Prazepam